The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 3.04 — safe zoneOK
Where the revenue comes from
Fiscal 2025, as Medpace Holdings, Inc. reports it. History and quarterly detail are in the app.
- Oncology$747.6M
- Other$745.0M
- Metabolic$408.5M
- AVAI$254.8M
- Central Nervous System$239.4M
Leadership changes
From Medpace Holdings, Inc.'s own filings, the day they're filed.
- Brad W. Hansman · President · appointmenteff. 2026-06-01
- Ashley M. Keating · member · departureeff. 2024-06-30
- Pathology Chairs · president · appointment
Latest filings
- 8-K · Company announcement2026-06-04
- 8-K · Company announcement2026-05-19
- 10-Q · Quarterly report2026-04-23
- 8-K · Company announcement2026-04-22
- DEF 14A · Annual proxy (pay & governance)2026-04-01
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Medpace Holdings, Inc., every answer cited🔒
- The Intelligence Brief — added when Medpace Holdings, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.